Bad Bugs Need Old Drugs: A Stewardship Program’s Evaluation of Minocycline for Multidrug-Resistant Acinetobacter baumannii Infections
Clinical Infectious Diseases November 15, 2014 V.59 N.10 S381-S387
Debra A. Goff1, Karri A. Bauer1, and Julie E. Mangino2,3
1Department of Pharmacy
2Division of Infectious Diseases, Department of Internal Medicine
3Department of Clinical Epidemiology, The Ohio State University Wexner Medical Center
Correspondence: Debra A. Goff, PharmD, FCCP, Specialty Practice Pharmacist Infectious Diseases, The Ohio State University Wexner Medical Center, Department of Pharmacy, 410 West 10th Ave, Rm 368 Doan Hall, Columbus, OH 43210 (firstname.lastname@example.org).
Minocycline is an “old-drug” with Food and Drug Administration approval for the treatment of infection due to Acinetobacter species. The purpose of this study is to describe an Antimicrobial Stewardship Program’s evaluation of minocycline for the treatment of patients with multidrug resistant A. baumannii (MDR-AB) infections.
This study evaluated hospitalized adult patients (September 2010 through March 2013) who received minocycline intravenously (IV) for a MDR-AB infection. Clinical and microbiological outcomes were analyzed. Secondary outcomes included infection-related mortality, length of hospital stay (LOS), infection-related LOS, intensive care unit (ICU) LOS, mechanical ventilation days, and 30-day readmission.
A total of 55 patients received minocycline. Median age was 56 (23–85) years, 65% were male with an APACHE II score of 21 (4–41). Clinical success was achieved in 40/55 (73%) patients treated with minocycline monotherapy (n = 3) or in combination with a second active agent (n = 52). Overall 43 (78%) patients demonstrated documented or presumed microbiologic eradication. Infection-related mortality was 25%. Hospital LOS was 31 (5–132) and infection-related LOS was 16 (2–43) days. Forty-seven (85%) patients were admitted to the ICU for a LOS of 18 (2–78) days. Thirty-nine (71%) patients required mechanical ventilation for 6 (2–29) days. One patient had a 30-day readmission.
The response rate to minocycline monotherapy or in combination for the treatment of MDR-AB infections is encouraging as therapeutic options are limited. Prospective studies in patients with MDR-AB infections will help establish the role of minocycline alone or in combination with other antimicrobials.